Enteric Disease Testing Market - By Disease (Bacterial [C. difficile, E. coli, Salmonella, Campylobacter], Viral [Rotavirus], Parasitic [Amebiasis, Giardiasis]), Test Type (Immunoassay, Molecular, Conventional), End-use - Global Forecast, 2024 - 2032

Enteric Disease Testing Market - By Disease (Bacterial [C. difficile, E. coli, Salmonella, Campylobacter], Viral [Rotavirus], Parasitic [Amebiasis, Giardiasis]), Test Type (Immunoassay, Molecular, Conventional), End-use - Global Forecast, 2024 - 2032

Global Enteric Disease Testing Market Size will witness around 3.9% CAGR from 2024 to 2032, driven by the rising prevalence of enteric diseases worldwide and the growing demand for accurate and rapid diagnostic solutions.

After conducting a fecal examination utilizing the BioFire® FilmArray® Gastrointestinal Panel assay, it was found that enteric infections had an overall prevalence of 86.1%. Among the identified pathogens, Enteroaggregative Escherichia coli (EAEC) constituted the highest proportion at 41.7%, followed by enteropathogenic E. coli (EPEC) at 40.8% and rotavirus A at 27.5%.

The increasing awareness about the importance of early diagnosis, advancements in molecular testing technologies, and the implementation of stringent regulations for food safety are propelling market expansion. Additionally, the surge in initiatives by governments and healthcare organizations to control the spread of enteric diseases is further fueling market growth.

The enteric disease testing market is classified based on disease, test type, end-use, and region.

The viral enteric disease segment will record significant growth through 2032 due to the rising prevalence of viral infections such as rotavirus, norovirus, and adenovirus. These infections pose substantial health risks, particularly among children and immunocompromised individuals. As a result, there is a growing demand for effective diagnostic tools capable of accurately identifying viral pathogens in clinical samples. The development of advanced molecular and immunological testing methods tailored for viral enteric pathogens could drive segmental growth in the coming years.

The enteric disease testing industry from the molecular test type segment will generate massive revenue by 2032 owing to the high sensitivity, specificity, and detection speed of molecular enteric disease testing. Molecular tests, including polymerase chain reaction (PCR), nucleic acid amplification techniques, and multiplex assays, offer several advantages over traditional culture-based methods, such as faster turnaround times and enhanced accuracy. These tests enable the simultaneous detection of multiple enteric pathogens from a single sample, facilitating prompt diagnosis and targeted treatment strategies. With ongoing advancements in molecular diagnostics and the introduction of automated platforms, the molecular test type segment is poised for substantial growth during the forecast period.

Europe Enteric Disease Testing market share will expand significantly through 2032, driven by robust healthcare infrastructure, increasing healthcare expenditure, and a high prevalence of enteric diseases. Countries in the region are witnessing a rising burden of enteric infections, necessitating the adoption of advanced diagnostic solutions for effective disease management and control. Moreover, stringent regulatory standards and guidelines about food safety and public health have propelled the demand for enteric disease testing in Europe. The presence of prominent market players, in line with ongoing R&D activities, further contributes to regional market growth.